ɂ‚ >> English Guide >> English Guide of JKMA

English Guide of JKMA

Business Plan for Fiscal 2016


Establishing a Business Plan

@@ JKMA is planning to review the result of its activities, identify future issues, and draw up a g2017 Medium-to-Long-Term Business Plan (Five Year Plan),h which will be implemented in 2017, because 2016 is the final year of its g2012 Medium-to-Long-Term Business Plan (Five Year Plan).h
@@ The key issues are the reliable procurement of raw materials for crude drugs and the quality assurance of the overall products, from raw materials for crude drugs to finished products. JKMA has united to address both domestic and international issues by establishing a cooperative framework with other associations.

@@ Firstly, JKMA will continue to achieve the reliable procurement of raw materials for crude drugs, by deepening its mutual understanding with China, the largest supplier of raw materials for crude drugs, and by sustaining the relationships with the associated organizations in China that were resumed in 2014. As for the promotion of domestic cultivation in Japan, JKMA will consider measures in an attempt to expand domestic cultivation based on the result of the Block Conference that has been held for three consecutive years since 2013.
@@ Secondly, in terms of the quality assurance of the overall products from raw materials for crude drugs to finished products, by affiliation of Japan as a member of the PIC/S, JKMA will make efforts to secure safety in terms of pesticide residue, heavy metals, microorganisms, aflatoxin. JKMA will also make efforts to disseminate gthe Handbook for Cultivation, Collection and Processing of Medicinal Plantsh, so-called gJKMA GACPh. With respect to GMP, JKMA will work to introduce an ICH Q10 drug quality system.

@@ JKMA will work on the following four common issues.
@@ - Comprehend and analyze the situation of ISO/TC249, and cooperate with the related administrative agencies and the Japan Liaison of Oriental Medicine (JLOM) in accordance with JKMAfs basic policy to avoid any impact on Kampo products, crude drug products and crude drugs in Japan. Respond to both domestic and international movements in drug GMP such as PIC/S in an appropriate manner.
@@ - Engage in the development and nourishing of Kampo products, crude drug products and crude drugs, secure safety, and promote their appropriate use in order to contribute to national medical care and public health.
@@ - For the public and stakeholder, improve the content of its website and engage in awareness-raising activities to raise awareness and improve understanding of Kampo products, crude drug products and crude drugs by continuously organizing Kampo seminars and making them accessible to public. Effectively provide member companies with information on JKMAfs businesses and each committeefs activities.
@@ - Raise the compliance awareness of member companies by continuously organizing workshops, because the entire pharmaceutical industry is asked to engage in initiatives to improve compliance and adherence to the code of conduct.

@@ While the extension of healthy life expectancy and the realization of a gsociety of health and longevityh are considered to be pivotal for the next 10 years or so under the governmentfs Japan Revitalization Strategy and Health and Medical Strategy, the role that Kampo products, crude drug products and crude drugs should play is expected to grow further. By working closely with its members, JKMA is determined to further improve its business activities and each committeefs activities, and contribute to the development of the pharmaceutical industry and public health by ensuring the stable supply, dissemination and establishment of high-quality Kampo products, crude drug products and crude drugs.